ESPR•benzinga•
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Summary
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse events, a New Drug Application is planned for late 2024.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2024 by benzinga